Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype

Cancer Research

Volumn 65, Issue 6, 2005, Pages 2441-2448

  Swinnen, Johannes V ^a   Beckers, Annelies ^a   Brusselmans, Koen ^a   Organe, Sophie ^a   Segers, Joanna ^a   Timmermans, Leen ^a   Vanderhoydonc, Frank ^a   Deboel, Ludo ^a   Derua, Rita ^a   Waelkens, Etienne ^a   De Schrijver, Ellen ^a   Van De Sande, Tine ^a   Noël, Agnès ^b   Foufelle, Fabienne ^c   Verhoeven, Guido ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; METHYLTESTOSTERONE; NUCLEOSIDE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOSYNTHESIS; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CULTURE; CELL ENERGY; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; FEMALE; HUMAN; HUMAN CELL; LIPOGENESIS; MOLECULAR MIMICRY; MOUSE; NONHUMAN; NUDE MOUSE; PHENOTYPE; PRIORITY JOURNAL; TUMOR CELL;

ADENOSINE MONOPHOSPHATE; ADENYLATE KINASE; AMINOIMIDAZOLE CARBOXAMIDE; ANIMALS; BIOMIMETIC MATERIALS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; ENERGY METABOLISM; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; RIBONUCLEOSIDES; RIBONUCLEOTIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 20144387628     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3025     Document Type: Article

References (42)

1. Kuhajda FP. Fatty acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000;16:202-8.
2. Pandolfi PP. Aberrant mRNA translation in cancer pathogenesis: an old concept revisited comes finally of age. Oncogene 2004;23:3134-7.
3. Abdulov S, Li S, Mochalek V, et al. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 2004;5:553-63.
4. Carling D. The AMP-activated protein kinase cascade: a unifying system for energy control. Trends Biochem Sci 2004;29:18-24.
5. Barford D, Johnson LN. The allosteric transition of glycogen phosphorylase. Nature 1989;340:609-16.
6. Claus TH, El-Maghrabi MR, Regen DM, et al. The role of fructose 2,6-bisphosphate in the regulation of carbohydrate metabolism. Curr Top Cell Regul 1984; 23:57-86.
7. Rakus D, Tillmann H, Wysocki R, Ulaszewski S, Eschrich K, Dzugaj A. Different sensitivities of mutants and chimeric forms of human muscle and liver fructose-I,6-bisphosphatases towards AMP. Biol Chem 2003;384:51-8.
8. Boudeau J, Sapkota G, Alessi DR. LKB1, a protein kinase regulating cell proliferation and polarity. FEBS Lett 2003;546:159-65.
9. Hawley SA, Boudeau J, Reid JL, et al. Complexes between the LKB1 tumor suppressor, STRADα/β and MO25 α/β are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003;2:28.1-28.16.
10. Woods A, Johnstone SR, Dickerson K, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003;13:2004-8.
11. Lizcano JM, Goransson O, Toth R, et al. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 2004;23: 833-43.
12. Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 2004;101:3329-35.
13. Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 2003;144:5179-83.
14. Carling D, Zammit VA, Hardie DG. A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett 1987;223:217-22.
15. Munday MR, Cambell DG, Carling D, Hardie DG. Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase. Eur J Biochem 1988;175:331-8.
16. Clarke PR, Hardie DG. Regulation of HMG-CoA reductase: identification of the site phosphorylated by the AMP-activated protein kinase in vitro and in intact rat liver. EMBO J 1990;9:2439-46.
17. Bolster DR, Crozier SJ, Kimball SR, Jefferson LS. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR signaling). J Biol Chem 2002;277:23977-80.
18. Horman S, Browne G, Krause U, et al. Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol 2002;12:1419-23.
19. Browne GJ, Finn SG, Proud CG. Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398. Oncogene 2004;23:3151-71.
20. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003;115:577-90.
21. Kuhajda FP, Jenner K, Wood FD, et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A 1994;91:6379-83.
22. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis in LNCaP prostate cancer cells. Cancer Res 2003;63:3799-804.
23. Jakobisiak M, Golab J. Potential antitumor effects of statins (Review). Int J Oncol 2003;23:1055-69.
24. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004;23:3151-71.
25. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004; 23:189-99.
26. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-Aminoimidazole-4- carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 1995;229:558-65.
27. Swinnen JV, Van Veldhoven PP, Esquenet M, Heyns W, Verhoeven G. Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology 1996; 137:4468-74.
28. Swinnen JV, Esquenet M, Goossens K, Heyns W, Verhoeven G. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res 1997;57:1086-90.
29. Ferré P, Azzout-Marniche D, Foufelle F. AMP-activated protein kinase and hepatic genes involved in glucose metabolism. Biochem Soc Trans 2003;31:220-3.
30. Swinnen JV, Van Veldhoven PP, Timmermans L, et al. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun 2003;302:898-903.
31. Muoio DM, Seefeld K, Witters LA, Coleman RA. AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Biochem J 1999;338:783-91.
32. Shen Z, Wen XF, Lan F, Shen ZZ, Shao ZM. The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma. Clin Cancer Res 2002;8:2085-90.
33. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002;16:509-19.
34. Kritchevsky D. Caloric restriction and cancer. J Nutr Sci Vitaminol (Tokyo) 2001;47:13-9.
35. Dirx MJM, Zeegers MPA, Dagnelie PC, Van den Bogaard T, Van den Brandt PA. Energy restriction and the risk of spontaneous mammary tumors in mice: a meta-analysis. Int J Cancer 2003;106:755-70.
36. Buhl ES, Jessen N, Pold R, et al. Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes 2002;51: 2199-206.
37. Carlson CL, Winder WW. Liver AMP-activated protein kinase and acetyl-CoA carboxylase during and after exercise. J Appl Physiol 1999;86:669-74.
38. Holmes BF, Kurth-Kraczek EJ, Winder WW. Chronic activation of 5′ AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J Appl Physiol 1999;87:1990-5.
39. Winder WW, Holmes BF, Rubinck DS, Jensen EB, Chen M, Holloszy JO. Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J Appl Physiol 2000;88:2219-26.
40. Thune I, Brenn T, Lund E, Gaard M. Physical activity and the risk of breast cancer. New Engl J Med 1997;336:1269-75.
41. Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr 2002;132:3456-648.
42. Dixon R, Gourzis J, McDermott D, Fujitaki J, Dewland P, Gruber H. AICA riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. J Clin Pharmacol 1991;31:342-7.